Literature DB >> 26487994

Organized Pneumonia Secondary to Increasing Doses of Temozolomide.

Pedro J Marcos1, Angélica Consuegra Vanegas2, María Matachana Martínez3, Lourdes Cordero Lorenzana3, Iria Vidal García2, Carmen Montero Martínez2.   

Abstract

Surgery, radiotherapy (RT), and chemotherapy have a role in the control of tumor growth, progression, and recurrence in high-grade gliomas. Temozolomide has been incorporated as the main chemotherapy agent for managing these tumors. Here, we present a case of a patient who developed a severe organizing pneumonia after increasing doses of temozolomide for a high-grade glioma.

Entities:  

Keywords:  glioma; organized pneumonia; side effects; temozolomide

Year:  2015        PMID： 26487994      PMCID： PMC4601909          DOI： 10.7759/cureus.318

Source DB:  PubMed          Journal:  Cureus        ISSN： 2168-8184


  10 in total

1.  A phase II study of temozolomide therapy for poor-risk patients aged >or=60 years with acute myeloid leukemia: low levels of MGMT predict for response.

Authors:  J M Brandwein; L Yang; A D Schimmer; A C Schuh; V Gupta; R A Wells; S M H Alibhai; W Xu; M D Minden
Journal:  Leukemia       Date:  2007-01-25       Impact factor: 11.528

2.  [Alveolo-interstitial pneumonia due to Temozolamide].

Authors:  L Guilleminault; P Carré; K de Luca; F Beau Salinas; E Autret-Leca; B Narciso; P Diot
Journal:  Rev Mal Respir       Date:  2008-09       Impact factor: 0.622

3.  A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.

Authors:  L E Abrey; J D Olson; J J Raizer; M Mack; A Rodavitch; D Y Boutros; M G Malkin
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

4.  A fatal case of acute interstitial pneumonia (AIP) in a woman affected by glioblastoma.

Authors:  Laura Balzarini; Chiara Mancini; Maurizio Marvisi
Journal:  Curr Drug Saf       Date:  2014-03

Review 5.  Bronchiolitis obliterans organizing pneumonia.

Authors:  G R Epler
Journal:  Arch Intern Med       Date:  2001-01-22

6.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

7.  Temozolomide-associated organizing pneumonitis.

Authors:  Fabien Maldonado; Andrew H Limper; Kaiser G Lim; Marie-Christine Aubrey
Journal:  Mayo Clin Proc       Date:  2007-06       Impact factor: 7.616

8.  Idiopathic organizing pneumonia: a relapsing disease. 19 years of experience in a hospital setting.

Authors:  Encarnacion Barroso; Luis Hernandez; Joan Gil; Raquel Garcia; Ignacio Aranda; Santiago Romero
Journal:  Respiration       Date:  2007-05-24       Impact factor: 3.580

9.  Hypersensitivity pneumonitis associated with the use of temozolomide.

Authors:  D Koschel; S Handzhiev; V Leucht; O Holotiuk; A Fisseler-Eckhoff; G Höffken
Journal:  Eur Respir J       Date:  2009-04       Impact factor: 16.671

10.  Temozolomide-associated bronchiolitis obliterans organizing pneumonia successfully treated with high-dose corticosteroid.

Authors:  Tae-Ok Kim; In-Jae Oh; Hyun-Wook Kang; Su-Young Chi; Hee-Jung Ban; Yong-Soo Kwon; Kyu-Sik Kim; Yu-Il Kim; Sung-Chul Lim; Young-Chul Kim
Journal:  J Korean Med Sci       Date:  2012-03-21       Impact factor: 2.153
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.